All In Biotech

Drug Trial Radar · NCT00883116

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy

Last checked: Nov 20, 2026Latest source record: Mar 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 551 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

551

Actual

Start

Aug 2009

Primary completion

Jun 2012

Study completion Feb 2014

Sponsor

Lead sponsor
R-PharmIndustry
Sponsor type
Industry
First posted
Apr 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed following first-line chemotherapy.

Conditions

  • Endometrial Cancer

Interventions

  • IxabepiloneDrug

  • DoxorubicinDrug

  • PaclitaxelDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Date of randomization to date of death or last date censored to up to approximately 26 months

Locations

93 sites in 19 countries. Site status is shown where the registry gives one.

  • University Of South Alabama

    Mobile, Alabama

  • Rocky Mountain Gynecologic Oncology

    Englewood, Colorado

  • Peter E. Schwartz, Md

    New Haven, Connecticut

  • Hematology Oncology, P.C.

    Stamford, Connecticut

  • Gynecologic Oncology Assoc.,Inc

    Hollywood, Florida

  • Florida Hospital Cancer Institute

    Orlando, Florida

  • Sarasota Memorial Health Care System

    Sarasota, Florida

  • H. Lee Moffitt Cancer Center

    Tampa, Florida

  • Georgia Health Science University

    Augusta, Georgia

  • Sudarshan K. Sharma, Md

    Hinsdale, Illinois

  • Central Dupage Hospital Cancer Center

    Warrenville, Illinois

  • St. Vincent Hospital And Health Care Center, Inc.

    Indianapolis, Indiana

  • Hematology And Oncology Specialists, Llc

    Marrero, Louisiana

  • Women'S Health Specialists

    Rockville, Maryland

  • Sparrow Regional Cancer Center

    Lansing, Michigan

  • University Of Minnesota

    Minneapolis, Minnesota

  • Saint Dominic's Gynecologic Oncology

    Jackson, Mississippi

  • Matthew A Powell, Md

    St Louis, Missouri

  • Blumenthal Cancer Center

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Peggy And Charles Stephenson Oklahoma Cancer Center

    Oklahoma City, Oklahoma

  • Tulsa Cancer Institute

    Tulsa, Oklahoma

  • Pennsylvania Oncology Hematology Associates

    Philadelphia, Pennsylvania

  • Magee-Womens Hospital Of Upmc Laboratory

    Pittsburgh, Pennsylvania

  • Women & Infants Hospital Of Ri

    Providence, Rhode Island

  • Cancer Centers Of The Carolinas

    Greenville, South Carolina

  • Tennessee Gynecologic Oncology Group, Llc

    Chattanooga, Tennessee

  • University Of Virginia

    Charlottesville, Virginia

  • Local Institution

    La Rioja, La Rioja Province, Argentina

  • Local Institution

    Salta, Salta Province, Argentina

  • Local Institution

    Rosario, Santa Fe Province, Argentina

  • Local Institution

    Milton, Queensland, Australia

  • Local Institution

    East Bentleigh, Victoria, Australia

  • Local Institution

    Ghent, Belgium

  • Local Institution

    Leuven, Belgium

  • Local Institution

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution

    Barretos, São Paulo, Brazil

  • Local Institution

    Jaú, São Paulo, Brazil

  • Local Institution

    São Paulo, São Paulo, Brazil

  • Local Institution

    Calgary, Alberta, Canada

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.